CDMO ViroCell Biologics has appointed Nick Maishman as Chief Operating Officer.
ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials: aiming to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Maishman brings over 30 years of commercial manufacturing, operations and quality management, and leadership experience. He has served as Site Head, General Manager, VP, and COO roles within pharmaceutical, biotech, vaccine and CDMO companies, such as GlaxoSmithKline, Pfizer, Valneva, Alexion and Recipharm respectively.
Maishman has worked across the globe including in the UK, Ireland, France, Greece, Austria, and USA. He also has significant experience leading the construction and start-up of new manufacturing sites, securing regulatory approval for CT and commercial GMP manufacturing, including among others for complex biologics such as monoclonal antibodies and vaccines.
His regulatory experience includes new product submissions to FDA and EMA and hosting site inspections from FDA, MHRA, European and International regulatory authorities.
Maishman was a key member of the start-up site leadership team at Pfizer, Grange Castle, a significant investment in vaccine and antibody manufacturing in Ireland. He also led the construction and start-up of the Alexion site in Dublin that manufactures products for ultra-rare diseases. He was Vice Principle of manufacturing for the vaccine company Valenva, where he also led the construction of a new facility for their Covid-19 vaccine.
Prior to joining ViroCell Biologics, he was Interim Chief Scientific and Operations Officer for Alliance Pharmaceuticals, a consumer health business with international operations. He has a BSc from Imperial College, London, and an MBA from the University of Warwick Business School.
The appointment of Maishman as COO comes shortly after the onboarding of Susan B. Nichols as Chief Business Officer in September.